Effect of alogliptin/pioglitazone on endothelial function and Visceral fat of Type 2Diabetes
Not Applicable
Completed
- Conditions
- Type2 diabetes
- Registration Number
- JPRN-UMIN000023463
- Lead Sponsor
- Dokkyo medical university hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1)Patients with hypersensitivity to the components of alogliptin or sulfonylurea. 2)Patients with severe ketosis ,diabetic coma or pre coma. 3)Patients with severe infection,before and after surgery,severe trauma. 4)Patient with advanced renal dysfunction(eGFR<30) or patient on dialysis. 5)Patients with severe liver dysfunction. 6)Patients with pregnancy or possibility. 7)Patients whom physician in charge considered inappropriate for study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Endothelial function after 6 months on pioglitazone or sulfonylurea
- Secondary Outcome Measures
Name Time Method The change of body weight,blood pressure,visceral fat HbA1c,blood glucose,LDL,HDL,non HDL,adiponectin,and 8epiPGF2A after 6 months treatment of pioglitazone or sulfonylurea